The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Abemaciclib plus fulvestrant vs fulvestrant alone for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy: Primary outcome of the phase 3 postMONARCH trial.
 
Kevin Kalinsky
Employment - EQRx (I); GRAIL (I)
Stock and Other Ownership Interests - EQRx (I); GRAIL (I)
Consulting or Advisory Role - 4D Pharma; AstraZeneca; Cullinan Oncology; Cullinan Oncology; Daiichi Sankyo/Astra Zeneca; eFFECTOR Therapeutics; Genentech/Roche; immunomedics; Lilly; Menarini Silicon Biosystems; Merck; mersana; Myovant Sciences; Novartis; Oncosec; Prelude Therapeutics; Puma Biotechnology; RayzeBio; RayzeBio; Seagen; Takeda
Research Funding - Ascentage Pharma (Inst); AstraZeneca (Inst); Daichi Sankyo (Inst); Genentech/Roche (Inst); Lilly (Inst); Novartis (Inst); Seagen (Inst)
Other Relationship - Genentech; Immunomedics
 
Giampaolo Bianchini
Honoraria - AstraZeneca/Daiichi Sankyo; Eisai; Exact Sciences; Gilead Sciences; Lilly; Menarini; MSD; Novartis; Pfizer; Roche; Seagen
Consulting or Advisory Role - Agendia; AstraZeneca; AstraZeneca/Daiichi Sankyo; Daiichi Sankyo Europe GmbH; Eisai; Exact Sciences; Gilead Sciences; Lilly; MSD; Novartis; Pfizer; Roche; Seagen
Research Funding - Gilead Sciences (Inst)
Travel, Accommodations, Expenses - AstraZeneca/Daiichi Sankyo; Gilead Sciences; Novartis; Pfizer; Roche
 
Erika P. Hamilton
Consulting or Advisory Role - Accutar Biotechnology (Inst); AstraZeneca (Inst); Daiichi Sankyo (Inst); Ellipses Pharma (Inst); Entos (Inst); Fosun Pharma (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Jazz Pharmaceuticals (Inst); Jefferies (Inst); Lilly (Inst); Medical Pharma Services (Inst); Mersana (Inst); Novartis (Inst); Olema Pharmaceuticals (Inst); Pfizer (Inst); Stemline Therapeutics (Inst); Tempus (Inst); Theratechnologies (Inst); Tubulis GmbH (Inst); Verascity Science (Inst); Zentalis (Inst)
Research Funding - Abbvie (Inst); Accutar Biotech (Inst); Acerta Pharma (Inst); ADC Therapeutics (Inst); Akeso Biopharma (Inst); Amgen (Inst); Aravive (Inst); ArQule (Inst); Artios (Inst); Arvinas (Inst); AstraZeneca (Inst); AtlasMedx (Inst); BeiGene (Inst); Black Diamond Therapeutics (Inst); Bliss Biopharmaceutical (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squib (Inst); Cascadian Therapeutics (Inst); Clovis Oncology (Inst); Compugen (Inst); Context Therapeutics (Inst); Cullinan Oncology (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Dana Farber Cancer Hospital (Inst); Dantari (Inst); Deciphera (Inst); Duality Biologics (Inst); eFFECTOR Therapeutics (Inst); Eisai (Inst); Ellipses Pharma (Inst); Elucida Oncology (Inst); EMD Serono (Inst); Fochon Pharmaceuticals (Inst); Fujifilm (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); H3 Biomedicine (Inst); Harpoon (Inst); Hutchison MediPharma (Inst); Immunogen (Inst); Immunomedics (Inst); Incyte (Inst); Infinity Pharmaceuticals (Inst); Inspirna (Inst); InventisBio (Inst); Jacobio (Inst); K-Group Beta (Inst); Karyopharm Therapeutics (Inst); Kind Pharmaceuticals (Inst); Leap Therapeutics (Inst); Lilly (Inst); Loxo (Inst); Lycera (Inst); MabSpace Biosciences (Inst); Macrogenics (Inst); MedImmune (Inst); Mersana (Inst); Merus (Inst); Millennium (Inst); Molecular Templates (Inst); Myriad Genetics (Inst); Novartis (Inst); Nucana (Inst); Olema Pharmaceuticals (Inst); OncoMed (Inst); Onconova Therapeutics (Inst); Oncothyreon (Inst); ORIC Pharmaceuticals (Inst); Orinove (Inst); Orum Therapeutics (Inst); Pfizer (Inst); PharmaMar (Inst); Pieris Pharmaceuticals (Inst); Pionyr (Inst); Plexxikon (Inst); Prelude Therapeutics (Inst); ProfoundBio (Inst); Radius Health (Inst); Regeneron (Inst); Relay Therapeutics (Inst); Repertoire Immune Medicines (Inst); Rgenix (Inst); Seagen (Inst); Sermonix Pharmaceuticals (Inst); Shattuck Labs (Inst); Silverback Therapeutics (Inst); Stem CentRx (Inst); Stemline Therapeutics (Inst); Sutro Biopharma (Inst); Syndax (Inst); Syros Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst); TapImmune Inc. (Inst); Tesaro (Inst); Tolmar (Inst); Torque (Inst); Treadwell Therapeutics (Inst); Verastem (Inst); Zenith Epigenetics (Inst); Zymeworks (Inst)
 
Stephanie L. Graff
Stock and Other Ownership Interests - HCA Healthcare
Honoraria - Academy for Continued Healthcare Learning; DAVA Oncology; IntegrityCE; Med IQ; Medical Educator Consortium; MedPage Today; MJH Life Sciences; Remedy Health; WebMD/Medscape; Wolters Kluwer
Consulting or Advisory Role - Daiichi Sankyo/Astra Zeneca; Genentech; Gilead Sciences; Lilly; Menarini; Novartis; Pfizer; Seagen
Research Funding - AstraZeneca/Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Loxo/Lilly; Novartis; Paxman
Other Relationship - Dr. Susan Love Foundation for Breast Cancer Research
 
Kyong Hwa Park
Stock and Other Ownership Interests - iMBDx
Honoraria - Celltrion
Consulting or Advisory Role - AstraZeneca; Daichi Sankyo
Patents, Royalties, Other Intellectual Property - IP transfer fee
Expert Testimony - LegoChem Biosciences
 
Rinath Jeselsohn
Consulting or Advisory Role - AstraZeneca; Carrick Therapeutics; Lilly; Novartis; Pfizer
Research Funding - Lilly; Pfizer
 
Umut Demirci
Honoraria - Abdi Ibrahim; AstraZeneca; AstraZeneca; BMS Turkey; CTGEN; Daiichi Sankyo/Astra Zeneca; Gen; Gilead Sciences; GlaxoSmithKline; Lilly; Menarini; Merck Serono; MSD; Novartis; Roche; Sandoz
Consulting or Advisory Role - Gilead Sciences; Menarini; MSD; Novartis
Travel, Accommodations, Expenses - AstraZeneca; Gen; Pfizer
 
Miguel Martin
Honoraria - Lilly; Novartis; Pfizer; Pierre Fabre; Roche/Genentech; SEAGEN
Consulting or Advisory Role - AstraZeneca; Daiichi-Sankyo; Lilly; Novartis; Pfizer; Roche/Genentech
Speakers' Bureau - Lilly/ImClone; Lilly/ImClone; Pierre Fabre; Roche/Genentech
Research Funding - Novartis (Inst); Puma Biotechnology (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Daichii-Sankyo
Other Relationship - Novartis; Roche
 
Rachel M. Layman
Honoraria - Pfizer
Consulting or Advisory Role - BioTheryX; Celcuity; Gilead Sciences; Lilly; Novartis
Research Funding - Accutar Biotech; Arvinas (Inst); Celcuity; GlaxoSmithKline (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Zentalis (Inst)
(OPTIONAL) Uncompensated Relationships - Celcuity; Lilly
 
Sara A. Hurvitz
Stock and Other Ownership Interests - ROM Tech (I)
Research Funding - Ambryx (Inst); Amgen (Inst); Arvinas (Inst); AstraZeneca/Daiichi Sankyo (Inst); Bayer (Inst); Biomarin (Inst); Cascadian Therapeutics (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Dantari (Inst); Dignitana (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Greenwich LifeSciences (Inst); Immunomedics (Inst); Lilly (Inst); Macrogenics (Inst); Merrimack (Inst); Novartis (Inst); OBI Pharma (Inst); Orinove (Inst); Orum (Inst); Pfizer (Inst); Phoenix Molecular Designs (Inst); Pieris Pharmaceuticals (Inst); Puma Biotechnology (Inst); Radius Health (Inst); Samumed (Inst); sanofi (Inst); Seagen (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - Lilly
Other Relationship - Pfizer; Roche
 
Sarah L Sammons
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Foundation Medicine; Loxo/Lilly; Novartis; Pfizer; Relay Therapeutics; Sermonix Pharmaceuticals
Research Funding - AstraZeneca/MedImmune (Inst); Lilly (Inst); Relay Therapeutics (Inst); Relay Therapeutics (Inst); Seagen (Inst); Sermonix Pharmaceuticals (Inst)
 
Peter A. Kaufman
Stock and Other Ownership Interests - Amgen; Johnson & Johnson/Janssen
Honoraria - AstraZeneca; Eisai; Lilly
Consulting or Advisory Role - AstraZeneca; Eisai; Lilly; Macrogenics; Merck; Pfizer; Polyphor; Roche/Genentech; Sanofi; Seagen; Sermonix Pharmaceuticals
Speakers' Bureau - Lilly
Research Funding - Eisai (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); Polyphor (Inst); Sanofi (Inst); Sermonix Pharmaceuticals (Inst); Zymeworks (Inst)
Expert Testimony - Seagen
Travel, Accommodations, Expenses - Lilly; Polyphor; Seagen
 
Montserrat Muñoz
Consulting or Advisory Role - Seagen
Speakers' Bureau - Esteve; Gilead Sciences; Gilead Sciences; Gilead Sciences; Roche; Roche
Expert Testimony - Novartis
Travel, Accommodations, Expenses - Gilead Sciences; Lilly; Lilly; Pfizer; Roche; Roche; Roche
 
Ling-Ming Tseng
No Relationships to Disclose
 
Holly Knoderer
Employment - Lilly
Stock and Other Ownership Interests - ADC Therapeutics; Athenex; Lilly; Lilly (I)
 
Bastien Nguyen
Employment - Lilly
 
Yanhong Zhou
Employment - Abbvie (I)
Stock and Other Ownership Interests - Abbvie (I); Lilly
Travel, Accommodations, Expenses - Lilly
 
Elizabeth Ravenberg
Employment - Lilly; MD Anderson Cancer Center
Stock and Other Ownership Interests - Lilly; Lilly
 
Lacey M Litchfield
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Seth Andrew Wander
Consulting or Advisory Role - AstraZeneca; Biovica; Foundation Medicine; Hologic; Lilly; Novartis; Pfizer; Puma Biotechnology; Veracyte
Speakers' Bureau - 2nd.MD; Guardant Health; Lilly; Novartis
Research Funding - Genentech; Lilly; Nuvation Bio; Pfizer; Regor Therapeutics; Sermonix Pharmaceuticals